Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
1.3400 x 80 1.4700 x 70
Post-market by (Cboe BZX)
1.4700 +0.1100 (+8.09%) 04/22/25 [NASDAQ]
1.3400 x 80 1.4700 x 70
Post-market 1.4700 unch (unch) 17:43 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3600
Day High
1.4800
Open 1.3900
Previous Close 1.3600 1.3600
Volume 1,608,900 1,608,900
Avg Vol 918,945 918,945
Stochastic %K 65.90% 65.90%
Weighted Alpha -76.65 -76.65
5-Day Change +0.2500 (+20.49%) +0.2500 (+20.49%)
52-Week Range 1.0100 - 13.4600 1.0100 - 13.4600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,664
  • Shares Outstanding, K 71,812
  • Annual Sales, $ 67,430 K
  • Annual Income, $ -165,840 K
  • EBIT $ -187 M
  • EBITDA $ -190 M
  • 60-Month Beta 1.80
  • Price/Sales 1.37
  • Price/Cash Flow N/A
  • Price/Book 0.27

Options Overview Details

View History
  • Implied Volatility 478.17% ( +57.43%)
  • Historical Volatility 100.95%
  • IV Percentile 95%
  • IV Rank 69.10%
  • IV High 686.04% on 04/08/25
  • IV Low 13.38% on 08/14/24
  • Put/Call Vol Ratio 10.00
  • Today's Volume 11
  • Volume Avg (30-Day) 80
  • Put/Call OI Ratio 2.02
  • Today's Open Interest 898
  • Open Int (30-Day) 1,685

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.67
  • Number of Estimates 7
  • High Estimate -0.52
  • Low Estimate -0.78
  • Prior Year 0.14
  • Growth Rate Est. (year over year) -578.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +45.54%
on 04/09/25
Period Open: 1.9100
2.0150 -27.05%
on 03/27/25
-0.4400 (-23.04%)
since 03/21/25
3-Month
1.0100 +45.54%
on 04/09/25
Period Open: 2.2600
2.6350 -44.21%
on 02/20/25
-0.7900 (-34.96%)
since 01/22/25
52-Week
1.0100 +45.54%
on 04/09/25
Period Open: 13.0000
13.4600 -89.08%
on 04/23/24
-11.5300 (-88.69%)
since 04/22/24

Most Recent Stories

More News
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTL : 1.4700 (+8.09%)
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

ZNTL : 1.4700 (+8.09%)
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

ZNTL : 1.4700 (+8.09%)
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

ZNTL : 1.4700 (+8.09%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTL : 1.4700 (+8.09%)
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

ZNTL : 1.4700 (+8.09%)
World Cancer Day Sparks Big Questions About Pollution, Genetics, and Innovation

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As World Cancer Day (Feb. 4) fades into the rearview, attention is shifting to the latest discussions...

ONCY : 0.6000 (+4.35%)
ZNTL : 1.4700 (+8.09%)
NYT : 50.12 (+2.58%)
ABSI : 3.21 (+4.56%)
GOVX : 0.8179 (+7.60%)
ONC.TO : 0.84 (+6.33%)
GSK : 36.63 (+0.49%)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

ZNTL : 1.4700 (+8.09%)
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ZNTL : 1.4700 (+8.09%)
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

ZNTL : 1.4700 (+8.09%)

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 1.6333
2nd Resistance Point 1.5567
1st Resistance Point 1.5133
Last Price 1.4700
1st Support Level 1.3933
2nd Support Level 1.3167
3rd Support Level 1.2733

See More

52-Week High 13.4600
Fibonacci 61.8% 8.7041
Fibonacci 50% 7.2350
Fibonacci 38.2% 5.7659
Last Price 1.4700
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.